Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs (Q37983912)

26 August 2017

title

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs (English)

1 reference

26 August 2017

1 reference

1 reference

Gina Song

1 reference

26 August 2017

Huali Wu

series ordinal

1 reference

26 August 2017

Keisuke Yoshino

series ordinal

1 reference

26 August 2017

William C Zamboni

series ordinal

1 reference

26 August 2017

publication date

15 February 2012

1 reference

Journal of Liposome Research

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

177-192

1 reference

Liposome disposition in vivo. III. Dose and vesicle-size effects

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Release of liposomal contents by cell-secreted matrix metalloproteinase-9

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Recent advances in non-viral gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Development of a highly stable and targetable nanoliposomal formulation of topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Targeted drug delivery to C6 glioma by transferrin-coupled liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Targeting liposomes toward novel pediatric anticancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Population pharmacokinetics of liposomal daunorubicin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Factors affecting toxicity and efficacy of polymeric nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Use of liposomal anthracyclines in Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Amphotericin B: side effects and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Degradation of poly (isobutyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pharmacokinetics and biodistribution of nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Novel temperature-sensitive liposomes with prolonged circulation time

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Liposomal anthracycline treatment for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Enzyme-activated targeting of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

A Novel Family ofl-Amino Acid-Based Biodegradable Polymer−Lipid Conjugates for the Development of Long-Circulating Liposomes with Effective Drug-Targeting Capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Development of ligand-targeted liposomes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Tumor targeting using anti-her2 immunoliposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Liposomal drug delivery systems: an update review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Ligand-targeted liposomal anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Effect of pazopanib on tumor microenvironment and liposome delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Recent advances with liposomes as pharmaceutical carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Nanoparticles for tumor targeted therapies and their pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Sterically stabilized liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Synthesis of a macromolecular camptothecin conjugate with dual phase drug release

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08982104.2012.655285

10.3109/08982104.2012.655285

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xjlax4kl3fg2zamhd24jz536r4

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_xjlax4kl3fg2zamhd24jz536r4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xjlax4kl3fg2zamhd24jz536r4

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/xjlax4kl3fg2zamhd24jz536r4

1 reference